Grifols, S.A. (ADR)

  • One Blood Management Company For Red Hot Returns

    By Madhukar Dubey - August 19, 2013 | Tickers: GRFS, HAE, PLL

    The global blood processing products and consumables market revenue is expected to grow at a CAGR of 8.9% over the next six years, to reach a market worth $49.16 billion in 2019. An increase in the aging population, growing number of cancer therapies, and rise in surgical operations are among few reasons responsible for this growth.

    Haemonetics (NYSE: HAE), market leader in the blood-collection equipment market with around more »

  • One Pharma Stock Investors Should Watch

    By Rashmi Singh - July 1, 2013 | Tickers: BAX, FMS, GRFS

    Baxter International (NYSE: BAX), one of the fastest-growing healthcare multinational corporations of America, has a long history of strong financial credentials. With a single-point agenda of emerging out as a clear leader in its core area of operations, Baxter has repeatedly proven its might.

    The FY 2012 growth story

    With FY 2012, the company wrapped up another successful business year. It achieved 5 % year-over-year growth in revenue (exclusive of foreign more »

  • Can This Small Pharma Company’s Investors Breathe Easy?

    By Arturo Cuevas - June 29, 2013 | Tickers: BAX, GRFS, KMDA

    Investors have reasons to be wary about small-cap biotech companies, particularly those ambitious start-ups which have been sprouting like mushrooms in the market this year. Many coming into the fray are companies which have yet to gain authorities’ approval for any of the drugs they are developing and thus are generally high-risk.

    There’s one recent market debut, though, where the trepidation seems lower — Kamada (NASDAQ: KMDA). This June, this more »

  • Billionaire John Paulson’s New Stock Picks

    By Meena Krishnamsetty - November 29, 2012 | Tickers: AGP, GRFS, NXY, SHPG, TMUS

    It’s been a tough few years for John Paulson’s Paulson & Co. After remarkable success shorting the housing bubble and, later, going long gold, his fund has struggled and is well down from its high water mark. Paulson is still a billionaire, however, and frequently followed by market watchers. His fund filed its 13F with the SEC in mid November, and we have compared it with previous filings to more »

  • Stop Vampires from Sucking your Portfolio Dry

    By Mike Steele - October 31, 2012 | Tickers: BAX, CMXHY.PK, GRFS, MKC, NKE, WY | Editor's Choice

    If there's one thing I have learned from watching too much Buffy the Vampire Slayer, it's that a plucky band of teenagers is the only thing standing between civilization and a dark future in which humanity becomes a weak all-you-can-eat buffet for a legion of vampires. And while you may have already put some thought into how to survive a vampire apocalypse, few if any people consider how more »

  • Catching the Spanish Flu

    By Eric Volkman - January 16, 2012 | Tickers: BBVA, SAN, GRFS, PT, TEF

    Following on the heels of our blog post about the possible fate of French American Depositary Receipts, we're turning our attention to the ADRs of Spanish and Portuguese companies. All three countries (plus six other European nations) had their sovereign debt downgraded by Standard & Poor's last week, with Portugal being particularly hard hit -- its paper was downgraded to junk status.

    The question this situation usually brings up is more »